Evolv Technologies Holdings, Inc. reaffirmed earnings guidance for the year ending December 31, 2022. For the year, the company expects revenue to be in range of $29 million to $31 million and net loss to be in the range of $83 million to $85 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.87 USD | +3.99% | +7.09% | -39.19% |
May. 22 | Lee Health Selects Evolv Technology For Weapons Detection | CI |
May. 21 | Virtua Health Adds Evolv Technology as its Weapons Detection Partner | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.19% | 431M | |
-6.08% | 42.08B | |
-3.84% | 10.53B | |
-11.17% | 7.36B | |
+4.25% | 6.37B | |
+14.77% | 3.15B | |
+44.96% | 1.91B | |
+5.56% | 1.68B | |
+6.00% | 1.54B | |
+2.60% | 1.48B |
- Stock Market
- Equities
- EVLV Stock
- News Evolv Technologies Holdings, Inc.
- Evolv Technologies Holdings, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2022